Status | Study |
NOT_YET_RECRUITING |
Study Name: Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis Condition: Candidiasis, Oral Date: 2023-11-01 Interventions: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days.The intervention soluti |
NOT_YET_RECRUITING |
Study Name: CelAgace� OraRinse Solution for Treatment of Candidiasis Condition: Candidiasis, Oral Date: 2017-08-10 Interventions: Oral rinse solution with each dose containing 100?g silver citrate complex and 40mg acemannan |
Completed |
Study Name: Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Condition: Candidiasis, Oral Stomatitis, Denture Date: 2016-06-21 Interventions: Other: Propolis Drug: Miconazole |
Completed |
Study Name: Effect of Probiotic Bacteria on Oral Candida in Frail Elderly Condition: Candidiasis Date: 2015-03-06 Interventions: Dietary Supplement: L. reuteri DSM 17938/ATCC PTA |
Completed |
Study Name: Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Condition: Candidiasis, Oral Date: 2014-07-08 Interventions: Drug: Roxanes's clotrimazole troches Drug: |
Completed |
Study Name: Oral Candida in Infants and Dietary Type Condition: Oral Candida Breastfeeding Bo Date: 2011-09-18 |
Completed |
Study Name: Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy Condition: Oral Candidiasis Date: 2008-10-07 Interventions: Dietary Supplement: Acidophilus |
Completed |
Study Name: Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Condition: Candidiasis, Oral Date: 2008-04-22 Interventions: Drug: Micafungin IV |
Completed |
Study Name: Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Condition: Candidiasis, Oral Date: 2008-04-22 Interventions: Drug: micafungin IV |
Completed |
Study Name: Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis Condition: Oral Candidiasis Date: 2008-03-18 Interventions: Drug: PAC113 PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days |